Gossamer Bio Ownership
| GOSS Stock | USD 0.70 0.04 6.06% |
Shares in Circulation | First Issued 2017-12-31 | Previous Quarter 238.5 M | Current Value 226.3 M | Avarage Shares Outstanding 91.2 M | Quarterly Volatility 66.1 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Gossamer |
Gossamer Stock Ownership Analysis
About 77.0% of the company shares are owned by institutional investors. The book value of Gossamer Bio was currently reported as 0.24. The company recorded a loss per share of 0.25. Gossamer Bio had not issued any dividends in recent years. Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California. Gossamer Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 185 people. To learn more about Gossamer Bio call the company at 858 684 1300 or check out https://www.gossamerbio.com.Gossamer Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Gossamer Bio is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Gossamer Bio backward and forwards among themselves. Gossamer Bio's institutional investor refers to the entity that pools money to purchase Gossamer Bio's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Silverarc Capital Management, Llc | 2024-06-30 | 5.5 M | T. Rowe Price Associates, Inc. | 2024-06-30 | 5.5 M | Eversept Partners, Llc | 2024-09-30 | 5 M | Hillhouse Capital Advisors, Ltd. | 2024-09-30 | 5 M | Monaco Asset Management | 2024-09-30 | 3.9 M | Deutsche Bank Ag | 2024-06-30 | 3.8 M | Opaleye Management Inc | 2024-09-30 | 3.7 M | Junked Platinum Investment Management Ltd | 2024-09-30 | 3.5 M | Ci Private Wealth Llc | 2024-06-30 | 3.4 M | Nea Management Company, Llc | 2024-06-30 | 18.1 M | Artal Group S A | 2024-06-30 | 13.3 M |
Gossamer Bio Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Gossamer Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Gossamer Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Gossamer Bio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Gossamer Bio Outstanding Bonds
Gossamer Bio issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Gossamer Bio uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Gossamer bonds can be classified according to their maturity, which is the date when Gossamer Bio has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Gossamer Stock Analysis
When running Gossamer Bio's price analysis, check to measure Gossamer Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gossamer Bio is operating at the current time. Most of Gossamer Bio's value examination focuses on studying past and present price action to predict the probability of Gossamer Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gossamer Bio's price. Additionally, you may evaluate how the addition of Gossamer Bio to your portfolios can decrease your overall portfolio volatility.